Tag:
Impax Labs
Latest Headlines
Latest Headlines
GlaxoSmithKline throws in the towel on $186M Parkinson's pact with Impax
A little more than two years after signing up GlaxoSmithKline as its Big Pharma partner on an extended-release version of a carbidopa-levodopa combo for Parkinson's disease, Impax Laboratories is headed back to the bargaining table. The FDA rejected the drug based on manufacturing issues a few months ago, and a frustrated Glaxo has now decided to drop out of the game.
Impax handed 12-page 483 at reevaluation
Impax Laboratories' struggles to get its manufacturing practices down at a plant in California where it intends to produce Rytary, an extended-release Parkinson drug, persist, the company has confessed. In fact, after reinspection of the plant, Impax received a Form 483 with a dozen observations, three of them repeats.
FDA stiff-arms Impax on extended-release Parkinson's combo
The FDA has thrown up a roadblock for Impax Laboratories' ($IPXL) extended-release version of a carbidopa-levodopa combo for Parkinson's disease now dubbed Rytary.
GlaxoSmithKline: Second PhIII Parkinson's drug study turns in winning data
GlaxoSmithKline says that the second of three planned Phase III studies for a reformulated Parkinson's treatment partnered with Impax Laboratories turned in positive numbers, with patients in the
Impax reveals warning letter related to drug recall
Inadequate sampling and testing has garnered Impax Labs a warning letter from the FDA for manufacturing violations. The Hayward, CA, drugmaker announced yesterday--prior to its posting on the FDA
Impax Labs' Parkinson's drug aces late-stage clinical trial
Impax Laboratories ( $IPXL ) is on a roll. The Hayward, CA-based developer announced Monday evening that the Parkinson's drug it in-licensed from GlaxoSmithKline last year--its second attempt at an
Shulman: Best biotech stocks to own
This morning, MarketWatch's Michael Shulman listed some of what he sees are the hottest bargain biotech stocks for this year: Cerus, Curis, Compugen, Spectrum Pharmaceuticals and Impax Laboratories.
Impax snares $186M deal from GSK on late-stage Parkinson's drug
With investigators at Impax Pharmaceuticals ( $IPXL ) preparing to reap a final round of late-stage data for their Parkinson's drug IPX066, GlaxoSmithKline ( $GSK ) has stepped up to license marketing
